This review synthesizes the cellular and physiological mechanisms, contrasts incretin-based therapies with lipid-lowering pharmacotherapy, summarizes the principal randomized trials, evaluates the distinction between plaque regression and plaque stabilization, and outlines unresolved questions and clinical-implementation considerations
Food and Drug Administration (FDA) took this into account and still deemed hydroquinone safe for topical application because not enough clear evidence of the risk outweighing the benefits exists
13 C NMR (100 MHz, DMSO-d 6 ) = 164.6, 163.5, 156.2, 151.5, 141.8, 128.5, 127.9, 127.7, 115.5, 111.7, 108.7, 91.6, 90.7, 89
If you are designing a study, the takeaway is that the strongest signal is in skin and connective-tissue models, the supporting literature concentrates around the Pickart groups body of work, and effects outside those model systems should be treated as more provisional
Expanded Access for Medicare Patients For the first time, Medicare will cover GLP-1 medications for obesity, starting mid-2026